14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TLX vs QURE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over uniQure N.V. (QURE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin), whereas QURE carries 48.9/100 (HOLD) at $22.10 (27.9x Forward P/E, -994.0% operating margin).
Composite vs. Pillar Nuance: While QURE currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. TLX 46.4/100 HOLD), TLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.2% vs. -994.0% operating margin) and revenue trajectory (+22.3% vs. +40.4% YoY).
Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile QURE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLX vs QURE. Trailing 12-month operating profitability (TLX 6.2% vs QURE -994.0%) and valuation multiples (TLX N/M vs QURE 27.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.7B market capitalization and -994.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ TLX vs QURE Key Questions & Quantitative Answers
As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over uniQure N.V. (QURE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin), whereas QURE carries 48.9/100 (HOLD) at $22.10 (27.9x Forward P/E, -994.0% operating margin). Composite vs. Pillar Nuance: While QURE currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. TLX 46.4/100 HOLD), TLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.2% vs. -994.0% operating margin) and revenue trajectory (+22.3% vs. +40.4% YoY). Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile QURE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TLX leads the Growth & Scale pillar: TLX posts +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin), compared with QURE at +40.4% YoY revenue growth and -18.2% YoY earnings growth on $20M TTM revenue (N/A gross margin, -994.0% operating margin). On trailing 12-month operating scale, TLX generates $891M in USD-normalized revenue versus $20M for QURE. In operating R&D and SG&A reinvestment, TLX deploys 41.4% of Rev ($369M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for QURE.
QURE screens cheaper on headline valuation multiples. TLX trades at N/M Forward P/E, 93.6x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (7.8% EBITDA margin), whereas QURE trades at 27.9x Forward P/E, 27.9x Trailing P/E, N/M PEG, and 83.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLX (7.4% ROE) versus QURE (-89.0% ROE) capital efficiency.
In options market volatility and institutional positioning, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 62% Vol realized risk). By comparison, QURE carries 56.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.81β · 81% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.